Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount

The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.

Companies Clinical Trials

Beam Therapeutics’ Base-Edited CAR-T Placed On Hold

Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.

Companies Clinical Trials

On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025

AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.

Commercial Companies

Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results

Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.

Companies Leadership

‘New GSK’ Raises Outlook After Shingrix Hits New Heights

The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.

Sales & Earnings Companies

Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch

The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.

Commercial Companies
See All
UsernamePublicRestriction

Register